Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma

Clin Drug Investig. 2014 Feb;34(2):159-61. doi: 10.1007/s40261-013-0159-9.

Abstract

Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / physiopathology
  • Humans
  • Iatrogenic Disease
  • Male
  • Receptors, Interleukin-6 / antagonists & inhibitors
  • Receptors, Interleukin-6 / immunology
  • Remission Induction / methods
  • Sarcoma, Kaposi / drug therapy*
  • Sarcoma, Kaposi / etiology
  • Sarcoma, Kaposi / pathology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Receptors, Interleukin-6
  • tocilizumab